尊敬的投資者，
我們誠摯邀請您參加藥明康德2022年一季度業績交流電話會，出席會議請撥打下圖電話號碼。
中文會議將于北京時間2022年4月26日上午9:00-9:50召開
英文會議將于北京時間2022年4月26日上午8:00-8:50召開
*非白名單用戶請通過海報內的鏈接預先注冊參會。
Dear Investors,
WuXi AppTec is pleased to invite you to our 1Q22 Results Webcast. We thank you for your interest and we sincerely hope you will join us.
English Webcast at 8:00-8:50 a.m., April 26, China time (8:00-8:50 p.m., April 25, 2022, EST)
Chinese Webcast at 9:00-9:50 a.m., April 26, China time
*Please sign up in advance for the English webcast through the link on the poster.
關于藥明康德
藥明康德（股票代碼：603259.SH/2359.HK）為全球生物醫藥行業提供一體化、端到端的新藥研發和生產服務，在亞洲、歐洲、北美等地均設有運營基地。藥明康德通過獨特的“CRDMO”和“CTDMO”業務模式，不斷降低研發門檻，助力客戶提升研發效率，為患者帶來更多突破性的治療方案，服務范圍涵蓋化學藥研發和生產、生物學研究、臨床前測試和臨床試驗研發、細胞及基因療法研發、測試和生產等領域。2021年，藥明康德被MSCI評為ESG（環境、社會及管治）AA級。目前，公司的賦能平臺正承載著來自全球30多個國家的5700多家合作伙伴的研發創新項目，致力于將更多新藥、好藥帶給全球病患，早日實現“讓天下沒有難做的藥，難治的病”的愿景。
About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,700 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
